Mizuho Lowers Embecta (NASDAQ:EMBC) Price Target to $5.00

Key Points

• Mizuho cut Embecta's price target from $12.00 to $5.00 and retained a "neutral" rating, implying roughly a 26.9% upside from the recent close.
• Q2 results missed expectations—EPS $0.27 vs. $0.42 and revenue $221.8M vs. $235.7M—revenue fell 14.4% year‑over‑year and management lowered FY‑2026 guidance to $1.55–$1.75 EPS with revenue below Street estimates.
• A Johnson Fistel investigation raises potential litigation risk that could add selling pressure, even as the board declared a $0.01 quarterly cash dividend.

Embecta (NASDAQ:EMBC - Get Free Report) had its price target lowered by Mizuho from $12.00 to $5.00 in a research note issued to investors on Wednesday, MarketBeat.com reports. The firm currently has a "neutral" rating on the stock. Mizuho's price target suggests a potential upside of 26.90% from the company's previous close.

Several other equities research analysts also recently weighed in on the stock. BTIG Research downgraded shares of Embecta from a "buy" rating to a "neutral" rating in a research note on Tuesday. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Embecta in a research note on Wednesday, January 21st. Finally, Wall Street Zen raised shares of Embecta from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 7th. Four research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Embecta currently has an average rating of "Hold" and a consensus price target of $15.00.

Embecta Trading Up 1.0%

EMBC traded up $0.04 during trading hours on Wednesday, hitting $3.94. 1,388,625 shares of the company's stock were exchanged, compared to its average volume of 983,088. Embecta has a 12-month low of $3.82 and a 12-month high of $15.55. The firm has a 50 day moving average of $9.12 and a 200 day moving average of $11.20. The firm has a market cap of $233.33 million, a P/E ratio of 1.69 and a beta of 1.09.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The business had revenue of $221.80 million for the quarter, compared to analysts' expectations of $235.67 million. During the same period in the previous year, the company earned $0.70 earnings per share. Embecta's quarterly revenue was down 14.4% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. As a group, research analysts expect that Embecta will post 2.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Embecta

A number of large investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of Embecta by 39.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 434,822 shares of the company's stock valued at $6,135,000 after buying an additional 123,113 shares in the last quarter. Jefferies Financial Group Inc. boosted its holdings in shares of Embecta by 40.4% in the 3rd quarter. Jefferies Financial Group Inc. now owns 1,884,875 shares of the company's stock valued at $26,596,000 after buying an additional 542,162 shares in the last quarter. Public Sector Pension Investment Board boosted its holdings in shares of Embecta by 57.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 314,129 shares of the company's stock valued at $4,432,000 after buying an additional 114,902 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Embecta by 365.7% in the 3rd quarter. Teacher Retirement System of Texas now owns 372,451 shares of the company's stock valued at $5,255,000 after buying an additional 292,477 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Embecta in the 4th quarter valued at $5,178,000. 93.83% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $0.01 per share (payable June 15, 2026; record date May 28). This provides a small income signal to holders. embecta Announces Quarterly Cash Dividend
• Neutral Sentiment: Quarterly earnings call/transcript and company materials are available for detail — useful for investors who want to assess management commentary on demand trends, margin drivers and cost actions. Embecta Q2 2026 Earnings Transcript
• Negative Sentiment: Q2 results missed across the board: EPS $0.27 vs. $0.42 expected, revenue $221.8M vs. $235.7M expected, and revenue down 14.4% y/y — evidence of demand weakness that pressures near‑term profitability. View Press Release
• Negative Sentiment: FY‑2026 guidance was lowered to $1.55–1.75 EPS and revenue guidance came in below Street expectations (~$1.0B vs. ~$1.1B consensus), widening the gap with analyst models and increasing downside risk to estimates and the stock. View Slide Deck
• Negative Sentiment: Johnson Fistel announced an investigation into potential claims on behalf of Embecta investors against executives — this raises litigation risk/uncertainty and can amplify selling pressure. Johnson Fistel Investigation Notice

Embecta Company Profile

Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.